CYPHFinancial Services · Asset Management

CYPH Stock Forecast: Cypherpunk Technologies, Inc. Price Predictions for 2026-2027

Last close, 25 Aug 2026

$1.64

−2.38% on the day

The 1 Wall Street analysts covering Cypherpunk Technologies, Inc. hold a median 12-month price target of $1.6 — -2.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 24 Aug 2026 — in the upper half.

Market cap

$153.0M

Ticker Nerd rank

58 / 100

Median analyst target

$1.60

Analysts covering

Revenue$0.0

Operating income−$4.8M

Net income−$77.2M

Free cash flow−$7.4M

Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown

Total return, dividends reinvested

+103.7%

+163.7%

YTD

+41.4%

+429.0%

From 52W high

−44.8%

From 52W low

+481.6%

$0.28

$2.97

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

CYPH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cypherpunk Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 24 Aug 2026

58 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth

Quality

Momentum

Size

Value

Volatility

Revisions

Issuance

Accruals

Growth (83): Sales and profits are climbing, and climbing faster than before.

Accruals (16): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CYPH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CYPH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $1.60Median $1.60High $1.60

The green dot is the last close — the median target sits −2.4% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
19 Aug 2026	Cantor Fitzgerald	Maintains	Overweight	$0.90 → $1.60
1 July 2026	Cantor Fitzgerald	Initiates	Overweight	$0.90
1 July 2026	Cantor Fitzgerald	Initiates	Overweight	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CYPH appears on the weeks it earns a place.

Performance

CYPH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 25 Aug 2026, Cypherpunk Technologies, Inc. returned +429.0% against +20.5% for the S&P 500, dividends included.

CYPH vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CYPH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Cypherpunk Technologies, Inc. (CYPH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 2.2×
Price / sales: —
Price / book: 1.1×
EV / EBITDA: −4.1×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −1.2%
Return on assets: −13.8%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cypherpunk Technologies, Inc. (CYPH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Cypherpunk Technologies, Inc. has a market value of $153.0M and an enterprise value of $145.4M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$56.9M.
Free cash flow in the twelve months to 31 Mar 2026: −$133.9M.
Shares outstanding: 93.9M.
Trailing P/E: 2.2×; forward P/E: −15.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Cypherpunk Technologies, Inc. employs 6 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

CYPH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelAsset Management

Company	Market cap	TKN rank
CYPHCypherpunk Technologies, Inc.	$153.0M	58
WHGWestwood Holdings Group, Inc.	$181.9M	84
HSDTSolana Co.	$126.4M	23
DFDVDeFi Development Corp.	$122.3M	16
SAMGSilvercrest Asset Management Group, Inc.	$117.2M	58
INVInnventure, Inc.	$115.1M	35
ZSTKZeroStack Corp.	$109.4M	27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cypherpunk Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CYPH news & analysis

Cypherpunk Technologies Looks Fully Valued After Zcash-Fueled Surge

Seeking Alpha · 25 Aug 2026neutral

Cypherpunk Technologies holds a significant ZEC treasury and has acquired a major Zcash mining operation, boosting its asset value. Recent ZEC price surges and the Zcash ETF launch have driven CYPH's valuation, but the stock's rapid rise has consumed much of its immediate upside, and its fully diluted share count and complex capital structure mean headline market cap understates the price investors pay for exposure.

Why it matters — A CYPH watcher would care because the stock's valuation may already reflect much of the benefit from its Zcash exposure, and the complex capital structure could mean investors are paying more than the headline market cap suggests.

Cypherpunk Technologies Launches World's Largest Zcash Mining Fleet

PRNewsWire · 18 Aug 2026positive

Cypherpunk Technologies announced the launch of Cypherpunk Mining, described as the world's largest Zcash mining fleet, via a $33.33 million equity-based transaction with Winklevoss Capital that activates 4.2 GSol/s of live, U.S.-based hashrate — approximately 18% of the Zcash network. Industry veteran Kevin Zhang joins as Head of Mining.

Why it matters — This transaction significantly expands Cypherpunk's mining operations and positions it as a major participant in the Zcash network, making it a notable development for CYPH watchers.

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

PRNewsWire · 12 Aug 2026neutral

Cypherpunk Technologies Inc. (Nasdaq: CYPH) reported its financial results for the second quarter ended June 30, 2026, announced via PRNewswire on Aug. 12, 2026.

Why it matters — CYPH watchers would care because the company's quarterly financial results provide key information about its recent performance.

Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research

PRNewsWire · 12 Aug 2026positive

Leap Therapeutics, the biotechnology subsidiary of Cypherpunk Technologies Inc. (CYPH), announced the publication of results from the randomized Phase 2 DeFianCe study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in Clinical Cancer Research. The peer-reviewed analyses establish baseline plasma DKK1 as a continuous quantitative biomarker predicting deepening sirexatamab benefit in second-line metastatic colorectal cancer patients, with improved response, progression-free survival, and overall survival when added to bevacizumab and chemotherapy in DKK1-high patients.

Why it matters — For CYPH watchers, this peer-reviewed publication validates the biomarker-driven clinical data behind the company's lead oncology asset, potentially informing the value of its biotechnology subsidiary.

FAQ

Frequently asked questions about CYPH stock

What is the CYPH stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Cypherpunk Technologies, Inc. have a median 12-month price target of $1.6, with estimates ranging from $1.6 to $1.6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CYPH stock a buy right now?

Of the 1 analysts covering Cypherpunk Technologies, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cypherpunk Technologies, Inc. 58 out of 100 across roughly 4,600 US stocks as at 24 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CYPH?

As at 24 Aug 2026, Cypherpunk Technologies, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (83 of 100).

Will CYPH stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies -2.4% from the last close, and Ticker Nerd's factor model ranks Cypherpunk Technologies, Inc. 58 out of 100 as at 24 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CYPH stock forecast for 2030?

No analyst covering Cypherpunk Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CYPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.6 to $1.6 over the next 12 months.

How has CYPH stock performed over the past year?

Cypherpunk Technologies, Inc. returned +429.0% over the 12 months to 25 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cypherpunk Technologies, Inc. do?

Cypherpunk Technologies Inc. is a biopharmaceutical company focused on developing novel antibody therapies for cancer treatment, with a strategic emphasis on biomarker-targeted approaches.

What is the latest news on CYPH?

The most recent item we track (Seeking Alpha, 25 Aug 2026): "Cypherpunk Technologies Looks Fully Valued After Zcash-Fueled Surge". Cypherpunk Technologies holds a significant ZEC treasury and has acquired a major Zcash mining operation, boosting its asset value. Recent ZEC price surges and the Zcash ETF launch have driven CYPH's valuation, but the stock's rapid rise has consumed much of its immediate upside, and its fully diluted share count and complex capital structure mean headline market cap understates the price investors pay for exposure.

Company

About Cypherpunk Technologies, Inc.

Cypherpunk Technologies Inc. is a biopharmaceutical company focused on developing novel antibody therapies for cancer treatment, with a strategic emphasis on biomarker-targeted approaches. The company’s lead clinical-stage candidate, DKN-01, is a monoclonal antibody designed to inhibit Dickkopf-related protein 1 and is currently being evaluated in multiple clinical trials for esophagogastric, gynecologic, and colorectal cancers. Additional pipeline assets include FL-301, targeting Claudin18.2-expressing cells, and preclinical programs FL-302 and FL-501. Cypherpunk Technologies also distinguishes itself with a unique digital asset treasury strategy, actively acquiring and holding Zcash (ZEC) as part of its long-term value-building initiative. The company’s research and development operations are conducted through its wholly-owned subsidiary, Leap Therapeutics, Inc. Headquartered in Cambridge, Massachusetts, Cypherpunk Technologies operates at the intersection of biotechnology innovation and digital asset investment, reflecting its dual commitment to advancing cancer therapies and supporting privacy-focused technologies.

CEO Mr. Douglas E. Onsi J.D. · 6 employees · United States · https://www.cypherpunk.com